Skip to main content
Top
Published in: BMC Public Health 1/2024

Open Access 01-12-2024 | Cervical Cancer | Research

Common predictors of cervical cancer related mortality in Ethiopia. A systematic review and meta-analysis

Authors: Hunduma Dina Hambisa, Berhane Teklay Asfaha, Biniam Ambisa, Abebech Gudeta Beyisho

Published in: BMC Public Health | Issue 1/2024

Login to get access

Abstract

Background

Cervical cancer accounts for 7.5% of all female cancer related deaths worldwide; peaking between the ages of 35 and 65, and not only kills young women but also destroys families with young children.

Objective

This review was intended to measure national level magnitude and the most common predictors of cervical cancer related mortality in Ethiopia.

Methods

Common Public databases like Science Direct, Embase, the Cochrane Library, and PubMed were thoroughly searched. The STATA 14 and Rev-Manager 5.3 statistical software packages were used for analysis, as well as a standardized data abstraction tool created in Microsoft Excel. The Cochrane Q-test statistics and the I2 test were used to assess non-uniformity. The pooled magnitude and predictors of cervical cancer related mortality were estimated using fixed-effect and random-effect models, respectively.

Result

The pooled mortality among cervical cancer patients was estimated that 16.39% at 95% confidence level fall in 13.89–18.88% in Ethiopia. The most common predictors of cervical cancer related mortality were late diagnosed, radiation therapy alone, and Being anemic were identified by this review. Among cervical cancer treatment modalities effectiveness of surgery with adjuvant therapy was also approved in this meta-analysis.

Conclusion and recommendation

In this study high cervical cancer-related mortality was reported as compared to national strategies to alleviate cervical cancer related mortality. Advanced implementation of cervical cancer screening at the national level for early diagnosis, anaemia detection, and combination anticancer therapy during initiation, as well as combination therapy, is critical to improve cervical cancer patient survival and decreasing mortality rates.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, et al. Erratum: global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca Cancer J Clin. 2020;70:313.CrossRef Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, et al. Erratum: global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca Cancer J Clin. 2020;70:313.CrossRef
3.
go back to reference Olusola P, Banerjee HN, Philley JV, Dasgupta S. (2019) Human Papilloma Virus-Associated Cervical Cancer and Health disparities. Cells 8. Olusola P, Banerjee HN, Philley JV, Dasgupta S. (2019) Human Papilloma Virus-Associated Cervical Cancer and Health disparities. Cells 8.
4.
go back to reference Jalil, Aat epidemiology of cervical cancer and high risk of human papilloma virus in patient. ББК 286 З 85. Jalil, Aat epidemiology of cervical cancer and high risk of human papilloma virus in patient. ББК 286 З 85.
5.
go back to reference Chen T, Wei M, Liu Y, Wang H, Zhou W, et al. Rising mortality rate of cervical cancer in younger women in urban China. J Gen Intern Med. 2020;35:593–3.PubMedCrossRef Chen T, Wei M, Liu Y, Wang H, Zhou W, et al. Rising mortality rate of cervical cancer in younger women in urban China. J Gen Intern Med. 2020;35:593–3.PubMedCrossRef
6.
go back to reference Burt LM, McCormak M, Lecuru F, Kanyike DM, Bvochora-Nsingo M, et al. Cervix Cancer in Sub-saharan Africa: an Assessment of Cervical Cancer Management. JCO Glob Oncol. 2021;7:173–82.PubMedCrossRef Burt LM, McCormak M, Lecuru F, Kanyike DM, Bvochora-Nsingo M, et al. Cervix Cancer in Sub-saharan Africa: an Assessment of Cervical Cancer Management. JCO Glob Oncol. 2021;7:173–82.PubMedCrossRef
7.
go back to reference Jordaan S, Michelow P, Richter K, Simoens C, Bogers J. A review of cervical cancer in South Africa: previous, current and future. Health Care Curr Rev. 2016;4:2. Jordaan S, Michelow P, Richter K, Simoens C, Bogers J. A review of cervical cancer in South Africa: previous, current and future. Health Care Curr Rev. 2016;4:2.
8.
go back to reference Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71:209–49.CrossRef Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71:209–49.CrossRef
9.
go back to reference Abate SM. Trends of Cervical Cancer in Ethiopia. Gynecology & Obstetrics s3; 2017. Abate SM. Trends of Cervical Cancer in Ethiopia. Gynecology & Obstetrics s3; 2017.
10.
go back to reference Moelle U, Mathewos A, Aynalem A, Wondemagegnehu T, Yonas B, et al. Cervical Cancer in Ethiopia: the Effect of Adherence to Radiotherapy on Survival. Oncologist. 2018;23:1024–32.PubMedPubMedCentralCrossRef Moelle U, Mathewos A, Aynalem A, Wondemagegnehu T, Yonas B, et al. Cervical Cancer in Ethiopia: the Effect of Adherence to Radiotherapy on Survival. Oncologist. 2018;23:1024–32.PubMedPubMedCentralCrossRef
11.
go back to reference Hoffman BL. Williams Gynecology. THIRDEDITION: McGraw-Hill Education; 2016. Hoffman BL. Williams Gynecology. THIRDEDITION: McGraw-Hill Education; 2016.
12.
go back to reference Health OW. (2007) Cancer Control: Knowledge into Action: WHO Guide for Effective Programmes: Module 2: Prevention. Geneva: © World Health Organization 2007. Health OW. (2007) Cancer Control: Knowledge into Action: WHO Guide for Effective Programmes: Module 2: Prevention. Geneva: © World Health Organization 2007.
13.
go back to reference Green JA, Kirwan JJ, Tierney J, Vale CL, Symonds PR, et al. Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. Cochrane database of systematic reviews; 2005. Green JA, Kirwan JJ, Tierney J, Vale CL, Symonds PR, et al. Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. Cochrane database of systematic reviews; 2005.
14.
go back to reference Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. J Clin Epidemiol. 2021;134:178–89.PubMedCrossRef Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. J Clin Epidemiol. 2021;134:178–89.PubMedCrossRef
15.
go back to reference Roever L. Critical appraisal of cohort studies. Evid Based Med Pract. 2015;1:e108. Roever L. Critical appraisal of cohort studies. Evid Based Med Pract. 2015;1:e108.
16.
go back to reference Amir-Behghadami M, Janati A. Population, intervention, comparison, outcomes and study (PICOS) design as a framework to formulate eligibility criteria in systematic reviews. Emergency Medicine Journal; 2020. Amir-Behghadami M, Janati A. Population, intervention, comparison, outcomes and study (PICOS) design as a framework to formulate eligibility criteria in systematic reviews. Emergency Medicine Journal; 2020.
17.
go back to reference Peterson J, Welch V, Losos M, Tugwell P. (2011) The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa: Ottawa Hospital Research Institute 2: 1–12. Peterson J, Welch V, Losos M, Tugwell P. (2011) The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa: Ottawa Hospital Research Institute 2: 1–12.
18.
go back to reference Aguade AE, Gashu C, Jegnaw T. The trend of change in cervical tumor size and time to death of hospitalized patients in northwestern Ethiopia during 2018–2022: retrospective study design. Health Sci Rep. 2023;6:e1121.PubMedPubMedCentralCrossRef Aguade AE, Gashu C, Jegnaw T. The trend of change in cervical tumor size and time to death of hospitalized patients in northwestern Ethiopia during 2018–2022: retrospective study design. Health Sci Rep. 2023;6:e1121.PubMedPubMedCentralCrossRef
19.
go back to reference Argefa TG, Roets L. Malnutrition and the survival of cervical cancer patients: a prospective cohort study using the PG-SGA tool. Nutr Cancer. 2022;74:605–12.PubMedCrossRef Argefa TG, Roets L. Malnutrition and the survival of cervical cancer patients: a prospective cohort study using the PG-SGA tool. Nutr Cancer. 2022;74:605–12.PubMedCrossRef
20.
go back to reference Begoihn M, Mathewos A, Aynalem A, Wondemagegnehu T, Moelle U, et al. Cervical cancer in Ethiopia–predictors of advanced stage and prolonged time to diagnosis. Infect Agents cancer. 2019;14:1–7.CrossRef Begoihn M, Mathewos A, Aynalem A, Wondemagegnehu T, Moelle U, et al. Cervical cancer in Ethiopia–predictors of advanced stage and prolonged time to diagnosis. Infect Agents cancer. 2019;14:1–7.CrossRef
21.
go back to reference Kantelhardt EJ, Moelle U, Begoihn M, Addissie A, Trocchi P, et al. Cervical cancer in Ethiopia: survival of 1,059 patients who received oncologic therapy. Oncologist. 2014;19:727–34.PubMedPubMedCentralCrossRef Kantelhardt EJ, Moelle U, Begoihn M, Addissie A, Trocchi P, et al. Cervical cancer in Ethiopia: survival of 1,059 patients who received oncologic therapy. Oncologist. 2014;19:727–34.PubMedPubMedCentralCrossRef
22.
go back to reference Gurmu SE. Assessing survival time of women with cervical cancer using various parametric frailty models: a case study at Tikur anbessa specialized hospital, Addis Ababa, Ethiopia. Annals Data Sci. 2018;5:513–27.CrossRef Gurmu SE. Assessing survival time of women with cervical cancer using various parametric frailty models: a case study at Tikur anbessa specialized hospital, Addis Ababa, Ethiopia. Annals Data Sci. 2018;5:513–27.CrossRef
23.
go back to reference Mebratie AE, Moges NA, Meselu BT, Melesse MF. Time to death from cervical cancer and predictors among cervical cancer patients in Felege Hiwot Comprehensive Specialized Hospital, North West Ethiopia: facility-based retrospective follow-up study. PLoS ONE. 2022;17:e0269576.PubMedPubMedCentralCrossRef Mebratie AE, Moges NA, Meselu BT, Melesse MF. Time to death from cervical cancer and predictors among cervical cancer patients in Felege Hiwot Comprehensive Specialized Hospital, North West Ethiopia: facility-based retrospective follow-up study. PLoS ONE. 2022;17:e0269576.PubMedPubMedCentralCrossRef
24.
go back to reference Gashu C, Tasfa B, Alemu C, Kassa Y. (2023) Assessing survival time of outpatients with cervical cancer: at the university of Gondar referral hospital using the bayesian approach. BMC Womens Health 23. Gashu C, Tasfa B, Alemu C, Kassa Y. (2023) Assessing survival time of outpatients with cervical cancer: at the university of Gondar referral hospital using the bayesian approach. BMC Womens Health 23.
25.
go back to reference Deressa BT, Assefa M, Tafesse E, Kantelhardt EJ, Soldatovic I, et al. Contemporary treatment patterns and survival of cervical cancer patients in Ethiopia. BMC Cancer. 2021;21:1–7.CrossRef Deressa BT, Assefa M, Tafesse E, Kantelhardt EJ, Soldatovic I, et al. Contemporary treatment patterns and survival of cervical cancer patients in Ethiopia. BMC Cancer. 2021;21:1–7.CrossRef
26.
go back to reference Fikeraddis T, Tigistu G, DHUGASA B. Treatment outcome and associated factors among cervical cancer patients treated at Tikur Anbesa Specializsed hospital Addis Ababa, Ethiopia a retrospective study. Oncology. 2018;3:12–29. Fikeraddis T, Tigistu G, DHUGASA B. Treatment outcome and associated factors among cervical cancer patients treated at Tikur Anbesa Specializsed hospital Addis Ababa, Ethiopia a retrospective study. Oncology. 2018;3:12–29.
27.
go back to reference Gizaw M, Addissie A, Getachew S, Ayele W, Mitiku I, et al. Cervical cancer patients presentation and survival in the only oncology referral hospital, Ethiopia: a retrospective cohort study. Infect Agents cancer. 2017;12:1–7.CrossRef Gizaw M, Addissie A, Getachew S, Ayele W, Mitiku I, et al. Cervical cancer patients presentation and survival in the only oncology referral hospital, Ethiopia: a retrospective cohort study. Infect Agents cancer. 2017;12:1–7.CrossRef
28.
go back to reference Seifu B, Fikru C, Yilma D, Tessema F. Predictors of time to death among cervical cancer patients at Tikur Anbesa specialized hospital from 2014 to 2019: a survival analysis. PLoS ONE. 2022;17:e0264369.PubMedPubMedCentralCrossRef Seifu B, Fikru C, Yilma D, Tessema F. Predictors of time to death among cervical cancer patients at Tikur Anbesa specialized hospital from 2014 to 2019: a survival analysis. PLoS ONE. 2022;17:e0264369.PubMedPubMedCentralCrossRef
29.
go back to reference Wassie M, Argaw Z, Tsige Y, Abebe M, Kisa S. Survival status and associated factors of death among cervical cancer patients attending at Tikur Anbesa Specialized Hospital, Addis Ababa, Ethiopia: a retrospective cohort study. BMC Cancer. 2019;19:1–11.CrossRef Wassie M, Argaw Z, Tsige Y, Abebe M, Kisa S. Survival status and associated factors of death among cervical cancer patients attending at Tikur Anbesa Specialized Hospital, Addis Ababa, Ethiopia: a retrospective cohort study. BMC Cancer. 2019;19:1–11.CrossRef
30.
go back to reference Israel H, Richter RR. A guide to understanding meta-analysis. J Orthop Sports Phys Therapy. 2011;41:496–504.CrossRef Israel H, Richter RR. A guide to understanding meta-analysis. J Orthop Sports Phys Therapy. 2011;41:496–504.CrossRef
32.
go back to reference Perera R, Heneghan C. Interpreting meta-analysis in systematic reviews. BMJ Evidence-Based Med. 2008;13:67–9.CrossRef Perera R, Heneghan C. Interpreting meta-analysis in systematic reviews. BMJ Evidence-Based Med. 2008;13:67–9.CrossRef
33.
go back to reference Hoy D, Brooks P, Woolf A, Blyth F, March L, et al. Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. J Clin Epidemiol. 2012;65:934–9.PubMedCrossRef Hoy D, Brooks P, Woolf A, Blyth F, March L, et al. Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. J Clin Epidemiol. 2012;65:934–9.PubMedCrossRef
34.
go back to reference Althabe F, Belizán JM, McClure EM, Hemingway-Foday J, Berrueta M, et al. A population-based, multifaceted strategy to implement antenatal corticosteroid treatment versus standard care for the reduction of neonatal mortality due to preterm birth in low-income and middle-income countries: the ACT cluster-randomised trial. Lancet. 2015;385:629–39.PubMedCrossRef Althabe F, Belizán JM, McClure EM, Hemingway-Foday J, Berrueta M, et al. A population-based, multifaceted strategy to implement antenatal corticosteroid treatment versus standard care for the reduction of neonatal mortality due to preterm birth in low-income and middle-income countries: the ACT cluster-randomised trial. Lancet. 2015;385:629–39.PubMedCrossRef
35.
go back to reference Basso O, Wilcox A. Mortality risk among preterm babies: immaturity vs. underlying pathology. Epidemiol (Cambridge Mass). 2010;21:521.CrossRef Basso O, Wilcox A. Mortality risk among preterm babies: immaturity vs. underlying pathology. Epidemiol (Cambridge Mass). 2010;21:521.CrossRef
36.
go back to reference Tshewang U, Satiracoo P, Lenbury Y. Survival analysis of Cervical Cancer patients: a case study of Bhutan. Asian Pac J Cancer Prevention: APJCP. 2021;22:2987.CrossRef Tshewang U, Satiracoo P, Lenbury Y. Survival analysis of Cervical Cancer patients: a case study of Bhutan. Asian Pac J Cancer Prevention: APJCP. 2021;22:2987.CrossRef
37.
go back to reference Balasubramaniam G, Gaidhani RH, Khan A, Saoba S, Mahantshetty U, et al. Survival rate of cervical cancer from a study conducted in India. Indian J Med Sci. 2021;73:203–11.CrossRef Balasubramaniam G, Gaidhani RH, Khan A, Saoba S, Mahantshetty U, et al. Survival rate of cervical cancer from a study conducted in India. Indian J Med Sci. 2021;73:203–11.CrossRef
38.
go back to reference Waxman AG. Guidelines for cervical cancer screening: history and scientific rationale. Clin Obstet Gynecol. 2005;48:77–97.PubMedCrossRef Waxman AG. Guidelines for cervical cancer screening: history and scientific rationale. Clin Obstet Gynecol. 2005;48:77–97.PubMedCrossRef
39.
go back to reference Carneiro SR, Fagundes MdA, do Rosário PdJO, Neves LMT, Souza GS et al. (2017) Five-year survival and associated factors in women treated for cervical cancer at a reference hospital in the Brazilian Amazon. PLoS One 12: e0187579. Carneiro SR, Fagundes MdA, do Rosário PdJO, Neves LMT, Souza GS et al. (2017) Five-year survival and associated factors in women treated for cervical cancer at a reference hospital in the Brazilian Amazon. PLoS One 12: e0187579.
40.
go back to reference Mehta N, Desai SM, Dhakad V, Patel D, Saldanha E. Treatment and outcomes of early and operable recurrent cervical Cancer: a prospective study. Niger J Surg. 2021;27:28–32.PubMedPubMedCentralCrossRef Mehta N, Desai SM, Dhakad V, Patel D, Saldanha E. Treatment and outcomes of early and operable recurrent cervical Cancer: a prospective study. Niger J Surg. 2021;27:28–32.PubMedPubMedCentralCrossRef
41.
go back to reference Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri: 2021 update. Int J Gynecol Obstet. 2021;155:28–44.CrossRef Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri: 2021 update. Int J Gynecol Obstet. 2021;155:28–44.CrossRef
42.
go back to reference Karimi H, Soleimanjahi H, Abdoli A, Banijamali RS. Combination therapy using human papillomavirus L1/E6/E7 genes and archaeosome: a nanovaccine confer immuneadjuvanting effects to fight cervical cancer. Sci Rep. 2020;10:1–15.CrossRef Karimi H, Soleimanjahi H, Abdoli A, Banijamali RS. Combination therapy using human papillomavirus L1/E6/E7 genes and archaeosome: a nanovaccine confer immuneadjuvanting effects to fight cervical cancer. Sci Rep. 2020;10:1–15.CrossRef
44.
go back to reference Nakamura H, Taguchi A, Kawana K, Baba S, Kawata A, et al. Therapeutic significance of targeting survivin in cervical cancer and possibility of combination therapy with TRAIL. Oncotarget. 2018;9:13451.PubMedPubMedCentralCrossRef Nakamura H, Taguchi A, Kawana K, Baba S, Kawata A, et al. Therapeutic significance of targeting survivin in cervical cancer and possibility of combination therapy with TRAIL. Oncotarget. 2018;9:13451.PubMedPubMedCentralCrossRef
45.
go back to reference Eckert F, Jelas I, Oehme M, Huber SM, Sonntag K, et al. Tumor-targeted IL-12 combined with local irradiation leads to systemic tumor control via abscopal effects in vivo. Oncoimmunology. 2017;6:e1323161.PubMedPubMedCentralCrossRef Eckert F, Jelas I, Oehme M, Huber SM, Sonntag K, et al. Tumor-targeted IL-12 combined with local irradiation leads to systemic tumor control via abscopal effects in vivo. Oncoimmunology. 2017;6:e1323161.PubMedPubMedCentralCrossRef
46.
go back to reference Fang M, Kan Y, Dong D, Yu T, Zhao N, et al. Multi-habitat based radiomics for the prediction of treatment response to concurrent chemotherapy and radiation therapy in locally advanced cervical cancer. Front Oncol. 2020;10:563.PubMedPubMedCentralCrossRef Fang M, Kan Y, Dong D, Yu T, Zhao N, et al. Multi-habitat based radiomics for the prediction of treatment response to concurrent chemotherapy and radiation therapy in locally advanced cervical cancer. Front Oncol. 2020;10:563.PubMedPubMedCentralCrossRef
47.
go back to reference Maduro JH, Pras E, Willemse PHB, de Vries EGE. Acute and long-term toxicity following radiotherapy alone or in combination with chemotherapy for locally advanced cervical cancer. Cancer Treat Rev. 2003;29:471–88.PubMedCrossRef Maduro JH, Pras E, Willemse PHB, de Vries EGE. Acute and long-term toxicity following radiotherapy alone or in combination with chemotherapy for locally advanced cervical cancer. Cancer Treat Rev. 2003;29:471–88.PubMedCrossRef
48.
go back to reference Dunst J, Kuhnt T, Strauss HG, Krause U, Pelz T, et al. Anemia in cervical cancers: impact on survival, patterns of relapse, and association with hypoxia and angiogenesis. Int J Radiation Oncology* Biology* Phys. 2003;56:778–87.CrossRef Dunst J, Kuhnt T, Strauss HG, Krause U, Pelz T, et al. Anemia in cervical cancers: impact on survival, patterns of relapse, and association with hypoxia and angiogenesis. Int J Radiation Oncology* Biology* Phys. 2003;56:778–87.CrossRef
49.
go back to reference Lim S, Lee C-M, Park J-M, Jung S-Y, Lee K-B. An association between preoperative anemia and poor prognostic factors and decreased survival in early stage cervical cancer patients. Obstet Gynecol Sci. 2014;57:471–7.PubMedPubMedCentralCrossRef Lim S, Lee C-M, Park J-M, Jung S-Y, Lee K-B. An association between preoperative anemia and poor prognostic factors and decreased survival in early stage cervical cancer patients. Obstet Gynecol Sci. 2014;57:471–7.PubMedPubMedCentralCrossRef
50.
go back to reference Koulis TA, Kornaga EN, Banerjee R, Phan T, Ghatage P, et al. Anemia, leukocytosis and thrombocytosis as prognostic factors in patients with cervical cancer treated with radical chemoradiotherapy: a retrospective cohort study. Clin Translational Radiation Oncol. 2017;4:51–6.CrossRef Koulis TA, Kornaga EN, Banerjee R, Phan T, Ghatage P, et al. Anemia, leukocytosis and thrombocytosis as prognostic factors in patients with cervical cancer treated with radical chemoradiotherapy: a retrospective cohort study. Clin Translational Radiation Oncol. 2017;4:51–6.CrossRef
51.
go back to reference Yanazume S, Karakida N, Higashi R, Fukuda M, Togami S, et al. Tumor bleeding requiring intervention and the correlation with anemia in uterine cervical cancer for definitive radiotherapy. Jpn J Clin Oncol. 2018;48:892–9.PubMedCrossRef Yanazume S, Karakida N, Higashi R, Fukuda M, Togami S, et al. Tumor bleeding requiring intervention and the correlation with anemia in uterine cervical cancer for definitive radiotherapy. Jpn J Clin Oncol. 2018;48:892–9.PubMedCrossRef
52.
go back to reference Candelaria M, Cetina L, Dueñas-González A. Anemia in cervical cancer patients: implications for iron supplementation therapy. Med Oncol. 2005;22:161–8.PubMedCrossRef Candelaria M, Cetina L, Dueñas-González A. Anemia in cervical cancer patients: implications for iron supplementation therapy. Med Oncol. 2005;22:161–8.PubMedCrossRef
53.
go back to reference Moreno–Acosta P, Carrillo S, Gamboa O, Romero–Rojas A, Acosta J, et al. Novel predictive biomarkers for cervical cancer prognosis. Mol Clin Oncol. 2016;5:792–6.PubMedPubMedCentralCrossRef Moreno–Acosta P, Carrillo S, Gamboa O, Romero–Rojas A, Acosta J, et al. Novel predictive biomarkers for cervical cancer prognosis. Mol Clin Oncol. 2016;5:792–6.PubMedPubMedCentralCrossRef
Metadata
Title
Common predictors of cervical cancer related mortality in Ethiopia. A systematic review and meta-analysis
Authors
Hunduma Dina Hambisa
Berhane Teklay Asfaha
Biniam Ambisa
Abebech Gudeta Beyisho
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2024
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/s12889-024-18238-x

Other articles of this Issue 1/2024

BMC Public Health 1/2024 Go to the issue